Condition: Acute Myeloid Leukemia · Hematopoietic and Lymphoid System Neoplasm · Myelodysplastic Syndrome · Sponsor: M.D. Anderson Cancer Center
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating patients with hematologic malignancies compared to ivosidenib and venetoclax alone.
This description comes directly from the study's public registry record.
Courtney DiNardo, MD · 713-794-1141 · cdinardo@mdanderson.org
Always discuss trial participation with your own doctor first.
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | Cleveland, Ohio, United States | Recruiting |
| Oregon Health and Science University | Portland, Oregon, United States | Recruiting |
| M D Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03471260